Bipolar Disorder Therapeutics Market Outlook:
Bipolar Disorder Therapeutics Market size was valued at USD 5.4 billion in 2025 and is projected to reach USD 7.1 billion by the end of 2035, rising at a CAGR of 3% during the forecast period, i.e., 2026-2035. In 2026, the industry size of bipolar disorder therapeutics is evaluated at USD 5.5 billion.
The market is highly driven by a surge in the patient population as there is a fast-rising prevalence of bipolar disorder across all nations. According to the World Health Organization report published in July 2024, the global patient base of bipolar disorder is reported to exceed 40 million cases, with the U.S. dominating with diagnosed cases. Therefore, this has resulted in the demand for advanced therapeutics to aid bipolar disorder, thereby positively influencing the bipolar disorder therapeutics sector. Besides, the supply chain relies on API manufacturers, with China dominating, the export of lithium APIs.
In contrast, the economic and trade sectors are leading the way, pushing business in the industry. For instance, the CAPLYTA, which is the FDA-approved drug for depressive episodes of bipolar I or II disorder, had a stellar sales growth by reaching USD 462 million in 2023, according to the SEC report. Research, development, and deployment investment remains strong. In addition, public and non-profit support is a major driver in allocating significant resources to psychiatric research, such as the development of novel therapeutic mechanisms and improved drug delivery systems for mood stabilizers and antipsychotics.
